{"name":"Stemline Therapeutics, Inc.","slug":"stemline-therapeutics-inc","ticker":"","exchange":"","domain":"stemline.com","description":"Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics. The company has a diverse pipeline of drug candidates in various stages of development, targeting significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":500000,"revenueGrowth":-44.3,"grossMargin":0,"rdSpend":50724411,"netIncome":-377600000,"cash":186979004,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MEN2501","genericName":"MEN2501","slug":"men2501","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"MEN2501","genericName":"MEN2501","slug":"men2501","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNV2p4NndlcGZJbHRzUWZEOW1TOHpMb0l5aVBHRGRuTzJGdjhSZDRCSk9GRXhMTnBneFlyZlVGNTVqS0VIVHlZQTMycUk2MUxOdkpIZFRxbDZQdE9lMjJVSzJIVmhWS1A5d2puU0tVeW5UTkl1LXdGMlk5YW92OC1sOFJyaGRBWnpWR1RnWV9lejFmSHJBVUsydWRRT3ZtcXlRZ2FqVk5falpDZDBieEUtMDNsTGxDbl84MTBSdW9YQjZVTGRmdl9zblRiNDM3V1N6Y3M0QUM1Y0lTSlN2amZsbmRZTThBb3A2M3lla2FydmZCS0ExV2xOQXE2WktVeDlaUGpGeFp4cFBQaFRqTmZzQ1VDVWlaOTVMWl8xT0JldlcwMUJWZDY4UlpMSnMwT0tZVERWdg?oc=5","date":"2026-03-09","type":"trial","source":"GlobeNewswire","summary":"Medidata Expands Partnership with The Menarini Group, - GlobeNewswire","headline":"Medidata Expands Partnership with The Menarini Group,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxOVGFHaWNsN0RzNFJYaGRoTzNtVFhMOU52VmxRSHJHRG9UeVlZczdKUUNCdUVEMnNwU0Q5TXJtQmN6RFNSanlFMWl0dVJhUmxoOXhRd1prdlVLenBURjdsRTh1cVhqcTFoVVgyWmJSMURobmJCNUNWZHMwSzJfVWNOU1RTWFRoOThteDcteXJobm5hdllibVJWeHBsR1ZsMmoxeW4tRm5KZGlqajBjam1Xcmo3a1ZaQW5Xal9hZFpzQUJ5VXl2dGlTQXZZLXVoNTg4bkxoNmlQdlgwbGpOUXY0V3puVUNkRjRlTXF6a3pEb1pCY1lWM1hGZFdCWHF4S0xENlZNRnc0cG5MWVdvYU94Z2JMY0JZdDR3dnRHS2Q0S18wWjdUQ3A0eXh2bHdDeFJkeUl0dkd3VkhCZFUxWUlwbm5FTVNHdUF6WVkw?oc=5","date":"2025-12-08","type":"trial","source":"PR Newswire","summary":"Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium - PR Newswire","headline":"Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Ca","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPUmktQ3pUdmd2ZmJOSm5GdThlWDFsbk5kT2FobElqTHJhcW1xTG8wRjNMM2s4UFZJR2M2MTlCbjdzNDcxbWpoZ1NLZ0wzcXJtZnlfdFd4UGg1YkxTbmtneWxYV3VwT3U1SnUyck9rbFhqVnE0bnpnYktMV3czb1pKX2stVnMzV1gwSEE4TW93dTFNdkNldUxPNmJ4bWw4Q0JYQXBQZEFnbnFTd01LQjMtWGlPY0VpR2pnODBGRHIxM2wtT2Z5eFRzdEE0bjN6X1JPc3ZudWxpMkpqSEk?oc=5","date":"2025-01-13","type":"deal","source":"Wilson Sonsini","summary":"Firm Advises Insilico on Patent Matters Related to Exclusive Global License Agreement with Menarini Group - Wilson Sonsini","headline":"Firm Advises Insilico on Patent Matters Related to Exclusive Global License Agreement with Menarini Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1xaFJISGJLQTNyeVVZS1kwWjhEWTdqeXN2di03TktqaTN1VldaamYydDlhUzJINlB3Q3FiNEl2VndRbzRnQjEtNmxVekh5cFVaT2Z0aFBXc1lDbzZ3?oc=5","date":"2025-01-10","type":"deal","source":"EurekAlert!","summary":"Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology - EurekAlert!","headline":"Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVm96Wm5YSlIxNEZ2WVlZaDNKMk9LRjA0M1RneXR6NEQ2ZVh4bzN1TDZ2T2c3aTJrUktSTzExdE5JbmQ4RWs5empzQ0FEN1ExMnNNY0dZLUlOZVpuRUtRTVpCZTFyenh1XzAxYUUtQkJjX053YkppTjNuMVRMUUxfMWhNaTFVWEZ5NjZnNXdXdXQ0Y3NwVkVmUWN5YmdHZ0F1UnNUaVpvengyTG5tLXZnMXZzdUFXZF9uWVRJ?oc=5","date":"2025-01-10","type":"deal","source":"Contract Pharma","summary":"Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine - Contract Pharma","headline":"Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNUXNPUFgtN2lEV1l5TVpKMmNOVTNISVFla0lNTUxCZXJQOW9hQnBNbjFiaGotVU9UT0E1cWcwR1ROX1k5eUNXZFJoYkkyLV82Q0hjaFlBNmRUM2tEY3VEWDdmTGRiWTU0Y1NUaG5rdGxJdUpudEZlTHBGNEFPazF4bWVHcjNGN29ubldUd0puQ0RZNjg5TE5tNEl6UWNJRWlRU0ZObHItWHkwaTYxSzlyeFV4dnh3ZnVaaTNKVldQdzZYc2xjWkpRaEJtdTRSOXZFY3k1RDlQWHpoeWRCdXNNTjlYUGdMS2s3?oc=5","date":"2024-12-12","type":"trial","source":"BioSpace","summary":"Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer - BioSpace","headline":"Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBOc284aHEzZGJDSmJJYko3aG5WbXRmV0lmTkUtOWU1WlBsZnF5ZVpJVjRxRjI2N0FqTnRobFZISE1GbDh0ZXNZMTlqSFNDSWZJY0Fjd2hNNXR5SUlhZnFQMmFrV1Q3MFVqUVBFYnBUWEhBZ2pMV3ppTUdR?oc=5","date":"2024-11-25","type":"trial","source":"Wiley","summary":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia - Wiley","headline":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yNFQ4bm56R0tOYjBXcU15Yk5ZNnV3eFJrY2V6dXlQY0JBVVU3SmlldFpCYk84eDFESHBGblhOZ0Q4WTFHaF96dVJ3cWhrekRUNGVsTzQwR3hKMEFv?oc=5","date":"2024-01-04","type":"deal","source":"EurekAlert!","summary":"Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications - EurekAlert!","headline":"Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential bre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gJBVV95cUxQQlhoelFkVU9sODZ6T0lmOW5GQ2R0anE5LXFLc3hqNHZmVEhlczNnaEVLZnAwaTBEN1NmVGw5MDJKVkpWMWRhYWpiSHdwZzRUYWpVNVgwY2NhMVdWaF8wcE9ZckJLRlpNOUtDY19ZUmNqMkpBN25VSGFyUnlYUXBuRmFtZnNmNTRnM2RpaXJ6U0tHX1RBRXVEWDU0cFZPSEdCczJYVk44T2hveFczU1QyOXBBNXdUTmhmdGxlNzlMQjQybUZhTUJJVW5wVDFPdERYZnR2QnVDc2hWYk1OYUkzWTVyWGZRcnlaZ0drb0I5cWdmX1pOLTRqQXRxM2k2RlFLbFhvLTFSTGs1S0hYeEdoWkt3M0dRWGc3WXNjUUFhRU8yVXhoQm5zVUN3eGdYSXUyUlVNdDFkcHZNbVRnQ0F3dk1YLXVVM3BYeUk5RmhjQ3B1REVMeWZmXzdGbXBwSjRUSHB5YjdXM1Y5MjdCb0E?oc=5","date":"2023-11-07","type":"deal","source":"Business Wire","summary":"Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer ","headline":"Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOQXFiTGJGVHluQkNrT0NtNWQ1cVVwNVdSM0otQzdSZl9NX21xbE5hdnU2eGZrc3d5SHhJUU1tRHBkcktzRWxRMGZKSVdxOFk0Qm1oQVVsV0xNS2NDQUh5S3drNXgySjRBUmpBOW5EZTQzVHJyMW4yYVdMZDBVWEdWNVNqVnZJeFBaS3VxbWF0SWI1b0pLQmxGS1JDZlFKMTRhMFZ3SzZneXdzcjVXNEQzQ3owZmV6NHhJSUZPYThkT1F5M1dxZ21SWURMUUF3aVJVZ3NHRlczM3BuLWs5UElCM2VvNTBsSGlJWFE?oc=5","date":"2023-08-31","type":"pipeline","source":"BioPharma APAC","summary":"Menarini's ELZONRIS® (Tagraxofusp) Receives Orphan Drug Designation for BPDCN by Japanese Ministry of Health - BioPharma APAC","headline":"Menarini's ELZONRIS® (Tagraxofusp) Receives Orphan Drug Designation for BPDCN by Japanese Ministry of Health","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-02-21","type":"regulatory","source":"Karyopharm","summary":"Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethas","headline":"Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOWHdqX19vOXNxa3pVODZTajUyUF9oZlh3Tk1YRGJTTGdYb1RIekV6bzBNZVl3TW1pOE4zNUlwbUMzY3VuZUI2X21YLU9adDFlTUJsNUNOZHdKamZxeU1BTFJJT21xVlF6cUc1c1JfY2VwNkdMb2JVRUF0LUVfU1FWaEVIRkJDYV9OWlFR?oc=5","date":"2020-05-05","type":"deal","source":"Pharmaceutical Technology","summary":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m - Pharmaceutical Technology","headline":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":500000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":500000,"period":"2018-12-31"},{"value":898199,"period":"2017-12-31"},{"value":1041354,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":50724411,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-377600000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":186979004,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}